Skip to content

PLx Pharma Winddown Corp.

Delisted

CIK 1497504fmd_0ND8K4MBYKB8R8QH7X325DKDXPManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 14, 2010 to Sep 30, 2022, 42 periods

Income Statement · Annual · Millions · USD
Line itemFY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021
Total revenues–––0011108
Cost of revenue––––––––05
Gross profit––––––––03
Research and development–2911044544
Selling, general and administrative––––––––940
Total operating expenses–4141951712151344
Operating income–(4)(14)(19)(5)(16)(11)(14)(13)(41)
Interest expense––––01110–
Interest and investment income––––0000––
Other non-operating income (expense)––––(0)(0)12(6)(2)(5)
Income before taxes––––(5)(16)1(21)(15)(46)
Income tax expense––00–(1)––00
Net income from continuing operations–––––(15)––(15)(46)
Net income(2)(4)(14)(19)(5)(15)1(21)(15)(46)